Other News To Note
Thursday, July 18, 2013
Biospecifics Technologies Corp., of Lynbrook, N.Y., said its partner Auxilium Pharmaceuticals Inc., of Malvern, Pa., has entered a collaboration with Swedish Orphan Biovitrum AB (Sobi), of Stockholm, for the long-term development, supply and commercialization of Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.